Recent progress of imaging agents for Parkinson's disease.
Recent progress of imaging agents for Parkinson's disease.
复制标题
帕金森氏病成像剂的最新进展。
DOI：
10.2174/1570159x13666141204221238
复制
发表时间：
2014-12
影响因子：
5.3
通讯作者：
Jia Z
中科院分区：
文献类型：
--
作者：
Wu X;Cai H;Ge R;Li L;Jia Z
帕金森病(PD)是一种常见的进行性、神经退行性疾病，由脑内线粒体功能障碍、氧化应激、蛋白质聚集和蛋白酶体功能障碍所致。与计算机断层扫描(CT)或磁共振成像(MRI)相比，非侵入性核放射性药物在不典型病例和临床前病例中具有较高的敏感性和特异性，对PD的早期诊断具有重要意义。基于配位化学和螯合剂设计的发展，放射性核素可以通过与PD相关的转运蛋白和受体(如多巴胺、5-羟色胺等)结合来传递到皮损。在这篇综述中，我们全面详细介绍了目前在帕金森病放射性核素成像方面的研究成果。
Parkinson's disease (PD) is a common progressive, neurodegenerative brain disease that is promoted by mitochondrial dysfunction, oxidative stress, protein aggregation and proteasome dysfunction in the brain. Compared with computer tomography (CT) or magnetic resonance imaging (MRI), non-invasive nuclear radiopharmaceuticals have great significance for the early diagnosis of PD due to their high sensitivity and specificity in atypical and preclinical cases. Based on the development of coordination chemistry and chelator design, radionuclides may be delivered to lesions by attaching to PD-related transporters and receptors, such as dopamine, serotonin, and others. In this review, we comprehensively detailed the current achievements in radionuclide imaging in Parkinson’s disease.